Clinical Trial Update: Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease [Phase 1]

View source ↗

Summary

A Phase 1 safety study of HPP854 in subjects with mild cognitive impairment or mild Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• HPP854

Snippet

Sponsor: High Point Pharmaceuticals, LLC. | Conditions: Mild Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | Status: TERMINATED